At the 3-year follow-up, Cemiplimab demonstrated further in OS and in patients with advanced NSCLC with PD-L1 ≥50%, despite a crossover rate of 75%: mOS 23.4 months (95% CI, 19.4–27.4) versus 13.7 (95% CI, 11.2–16.2), HR, 0.63 (95% CI, 0.52–0.77); p = 0.0001 [61]. Here, CD274 is linked to non-small cell lung carcinoma.